US20020028946A1 - Process for the preparation of heteroaryl-phenylalanines - Google Patents

Process for the preparation of heteroaryl-phenylalanines Download PDF

Info

Publication number
US20020028946A1
US20020028946A1 US09/331,164 US33116499A US2002028946A1 US 20020028946 A1 US20020028946 A1 US 20020028946A1 US 33116499 A US33116499 A US 33116499A US 2002028946 A1 US2002028946 A1 US 2002028946A1
Authority
US
United States
Prior art keywords
formula
group
compound
groups
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/331,164
Other versions
US6448408B1 (en
Inventor
Marco Villa
Maurizio Paiocchi
Katiuscia Arrighi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon Group SpA
Original Assignee
Zambon Group SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Group SpA filed Critical Zambon Group SpA
Assigned to ZAMBON GROUP S.P.A. reassignment ZAMBON GROUP S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARRIGHI, KATIUSCIA, PAIOCCHI, MAURIZIO, VILLA, MARCO
Publication of US20020028946A1 publication Critical patent/US20020028946A1/en
Application granted granted Critical
Publication of US6448408B1 publication Critical patent/US6448408B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to a process for the preparation of heteroaryl-phenylalanines and, more particularly, it relates to a cross-coupling process for the preparation of phenylalanine derivatives having the phenyl group substituted by a heteroaryl group.
  • Heteroaryl-phenylalanines are known compounds, well described in the literature. For example, heteroaryl-phenylalanines endowed with pharmacological activity as antihypertensive agents have been described in the British patent n° 1554667 (Merck & Co., Inc.).
  • heteroaryl-phenylalanines can be used as synthetic intermediates for the preparation of compounds endowed with pharmacological activity.
  • heteroaryl-phenylalanines are used for the preparation of N-mercaptoacyl derivatives of phenylalanine of formula
  • R is a hydrogen atom, a straight or branched C 1 -C 4 alkyl group or a benzyl group
  • R 1 is a 5 or 6 membered aromatic heterocyclic group, optionally substituted, having 1 or 2 heteroatoms selected among nitrogen oxygen and sulphur;
  • R 2 is a C 2 -C 4 straight or branched alkyl group or an aryl or arylalkyl group having from 1 to 6 carbon atoms in the alkyl moiety in which the aryl group is phenyl or a 5 or 6 membered aromatic heterocyclic group having 1 or 2 heteroatoms selected among nitrogen, oxygen and sulphur, optionally substituted by one or more substituents, the same or different, selected among halogen atoms, hydroxy groups, alkoxy, alkyl, alkylthio, alkylsulfonyl or alkoxycarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety, C 1 -C 3 alkyl groups comprising one or more fluorine atoms, carboxy groups, nitro groups, amino or aminocarbonyl groups, acylamino groups, aminosulfonyl groups, mono- or di-alkylamino or mono- or di-alkylaminocarbonyl groups having
  • R 3 is a mercapto group or a R 4 COS group convertible into a mercapto group in the body in which R 4 is a straight or branched C 1 -C 4 alkyl group or a phenyl group.
  • Such compounds are endowed with metallopeptidases inhibitory activity and are useful in therapy for the treatment of cardiovascular diseases.
  • 4-(2-furanyl)-phenylalanine is prepared following a cross-coupling process comprising the reaction between N-(tert-butoxycarbonyl)-tyrosine triflate methyl ester and 2-furanboronic acid in the presence of palladium(0)tetrakis(triphenylphosphine) as described by W. C. Shieh in J Org Chem. 1992, 57, 379-381.
  • arylboronic derivatives used as synthetic intermediates in the above processes are in turn prepared from the corresponding aryl-magnesium or aryl-lithium derivatives, by reaction with trialkylborates.
  • the heteroaryl-phenylalanines can be prepared by cross-coupling between halogenated heterocyclic derivatives and stannyl-phenylalanine derivatives (Bioconjugate Chem., 1993, 4, 574-580); nevertheless the alkyistannanes used for the preparation of stannyl-phenylalanines are highly toxic compounds.
  • object of the present invention is a process for the preparation of heteroaryl-phenylalanines of formula
  • R is a hydrogen atom, a straight or branched C 1 -C 4 alkyl groups or a benzyl group
  • R 1 is an optionally substituted 5 or 6 membered aromatic heterocyclic group with one or two heteroatoms selected among nitrogen, oxygen and sulphur;
  • R 1 has the above reported meanings and Y is a chlorine, bromine or iodine atom; and a compound of formula
  • R′ is an optionally protected amino group
  • X is an iodine or bromine atom or a methansulfonyloxy, fluoromethansulfonyloxy, p toluensulfonyloxy or trifluoromethansulfonyloxy group;
  • the process object of the present invention is easily practicable and it enables to obtain the heteroaryl-phenylalanines of formula II with high yields, equal to or greater than 80% with respect to the starting compound of formula IV.
  • the cross-coupling reaction is carried out by reaction between an organo-zinc compound of formula III and a compound of formula IV.
  • compound III and compound IV are used in a molar ratio III:IV from 1:1 to 3:1.
  • the molar ratio of the compounds III:IV is from 1:1 to 2:1.
  • the cross-coupling reaction is carried out in the presence of a transition-metal(0) based catalyst.
  • the amount of the catalyst is preferably from 0.05% to 5% in moles with respect to the organo-zinc compound of formula III.
  • transition-metal(0) based catalysts are optionally supported palladium or nickel, in the presence of ligands such as, for example, triphenylphosphine.
  • transition-metal(0) based catalysts can be optionally prepared in situ starting from the corresponding salts such as, for example, nickel chloride, cobalt chloride, nickel acetylacetonate, ferric chloride, palladium chloride, lithium tetrachlorocuprate, palladium acetate and palladium acetylacetonate.
  • salts such as, for example, nickel chloride, cobalt chloride, nickel acetylacetonate, ferric chloride, palladium chloride, lithium tetrachlorocuprate, palladium acetate and palladium acetylacetonate.
  • the cross-coupling reaction is carried out in the presence of an organic solvent.
  • Suitable organic solvents are, for example, C 6 -C 12 aliphatic hydrocarbons, tetrahydrofuran, di-ethyl ether, methyl-lert-butyl ether, ethylene glycol di-methyl ether, dioxane, toluene, xylene or mixtures thereof.
  • tetrahydrofuran, toluene or mixtures thereof are used.
  • reaction temperature is between 20° C. and the reflux temperature of the reaction mixture.
  • a temperature between 40° C. and 60° C. is used.
  • Suitable protecting groups are acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, formyl, benzyl, ethoxycarbonyl and phthaloyl.
  • the protective group is tert-butoxycarbonyl or formyl.
  • R′ is a protected amino group
  • the compounds of formula II according to the present process are prepared by cross-coupling reaction and subsequent deprotection of the amino group.
  • the cross-coupling reaction is carried out starting from a compound of formula IV in which R is different from hydrogen, hence obtaining the corresponding compounds of formula II (R different from hydrogen). From these, by working according to conventional procedures, the corresponding compounds of formula II in which R ⁇ H can be obtained.
  • the starting compounds of formula III are known compounds or they are easily prepared according to known methods.
  • the compounds of formula III can be prepared by reaction of the corresponding heteroaryl-lithium or heteroaryl-magnesium derivatives with an anhydrous zinc halide, e.g. zinc chloride, as likewise reported in Heterocycles, Vol. 31, No 12, 1990, 2181-2186.
  • anhydrous zinc halide e.g. zinc chloride
  • Examples of compounds of formula II, that can be prepared according to the process object of the present invention are the compounds in which the R 1 group is an aromatic heterocyclic group such as, for example, thiazole, isoxazole, oxazole, isothiazole, pyrazole, imidazole, thiophene, pyrrole, pyridine, pyrimidine, pyrazine, pyridazine and furan.
  • the starting compounds of formula III are prepared in situ from the corresponding heteroaryl-lithium or heteroaryl-magnesium derivatives and hence directly used in the cross-coupling reaction.
  • heteroaryl-lithium or heteroaryl-magnesium derivatives are reacted with an anhydrous zinc halide, in the presence of the same solvent used for the cross-coupling reaction, to obtain the corresponding heteroaryl-zinc derivatives of formula III.
  • heteroaryl-zinc derivatives of formula III are prepared with anhydrous zinc chloride.
  • heteroaryl-lithium or heteroaryl-magnesium derivatives are known compounds or they are easily prepared according to known methods, as described, for example. in J. Am. Chem. Soc. 1952, 74, 6260-6262 or in the just mentioned Heterocycles, Vol. 31, No. 12, 1990, 2181-2186.
  • the compounds of formula II are prepared starting from the corresponding heteroaryl-magnesium derivatives, by their reaction with an anhydrous zinc halide and subsequent cross-coupling reaction of the resultant compounds of formula III, in the same medium, as previously described.
  • the compounds of formula II can be used as synthetic intermediates for the preparation of compounds endowed with pharmacological activity such as, for example, the N-mercaptoacyl derivatives of phenylalanine of formula I, as disclosed in the just mentioned International patent application no. WO 97/24342.
  • the process object of the present invention is used for the preparation of the compounds endowed with pharmacological action described in the aforesaid International patent application.
  • a suitable amount of heteroaryl-magnesium halide is treated with an anhydrous zinc halide in a molar ratio respectively equal to 1:2, at room temperature and in the presence of a suitable solvent.
  • the cross-coupling reaction is carried out in the presence of catalytic amounts, for example equal to 1% in moles, of an in situ prepared palladium based catalyst.
  • the resultant compounds of formula II can be used as such, for example as synthetic intermediates for the preparation of pharmacologically active compounds.
  • the process object of the present invention is easily practicable and it enables to obtain the heteroaryl-phenylalanines of formula II with high yields and with mild reaction conditions.
  • the process object of thre present invention enables to obtain the compounds of formula II with a high optical purity, without any racemization.
  • N-formyl-4-iodo-L-phenylalanine methyl ester was obtained (yield>90%) as a crude to be used as such without any further purification.

Abstract

Figure US20020028946A1-20020307-C00001
A process for the preparation of heteroaryl-phenylalanines of formula (II) in which R is a hydrogen atom, a straight or branched C1 -C4 alkyl groups or a benzyl group; R1 is an optionally substituted 5 or 6 membered aromatic heterocyclic group with one or two heteroatoms selected among nitrogen, oxygen and sulphur; comprising a cross-coupling reaction among heteroaryl-zinc halide and phenylalanine derivatives is described. Compounds of formula (II) are intermediates useful for the preparation of compounds endowed with pharmacological activity.

Description

  • The present invention relates to a process for the preparation of heteroaryl-phenylalanines and, more particularly, it relates to a cross-coupling process for the preparation of phenylalanine derivatives having the phenyl group substituted by a heteroaryl group. [0001]
  • Heteroaryl-phenylalanines are known compounds, well described in the literature. For example, heteroaryl-phenylalanines endowed with pharmacological activity as antihypertensive agents have been described in the British patent n° 1554667 (Merck & Co., Inc.). [0002]
  • Moreover, heteroaryl-phenylalanines can be used as synthetic intermediates for the preparation of compounds endowed with pharmacological activity. [0003]
  • In the International patent application no. WO 97/24342 in the name of the same applicant, heteroaryl-phenylalanines are used for the preparation of N-mercaptoacyl derivatives of phenylalanine of formula [0004]
    Figure US20020028946A1-20020307-C00002
  • wherein [0005]
  • R is a hydrogen atom, a straight or branched C[0006] 1-C4 alkyl group or a benzyl group;
  • R[0007] 1 is a 5 or 6 membered aromatic heterocyclic group, optionally substituted, having 1 or 2 heteroatoms selected among nitrogen oxygen and sulphur;
  • R[0008] 2 is a C2-C4 straight or branched alkyl group or an aryl or arylalkyl group having from 1 to 6 carbon atoms in the alkyl moiety in which the aryl group is phenyl or a 5 or 6 membered aromatic heterocyclic group having 1 or 2 heteroatoms selected among nitrogen, oxygen and sulphur, optionally substituted by one or more substituents, the same or different, selected among halogen atoms, hydroxy groups, alkoxy, alkyl, alkylthio, alkylsulfonyl or alkoxycarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety, C1-C3 alkyl groups comprising one or more fluorine atoms, carboxy groups, nitro groups, amino or aminocarbonyl groups, acylamino groups, aminosulfonyl groups, mono- or di-alkylamino or mono- or di-alkylaminocarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety;
  • R[0009] 3 is a mercapto group or a R4COS group convertible into a mercapto group in the body in which R4 is a straight or branched C1-C4 alkyl group or a phenyl group.
  • Such compounds are endowed with metallopeptidases inhibitory activity and are useful in therapy for the treatment of cardiovascular diseases. [0010]
  • Many processes for the preparation of heteroaryl-phenylalanines are described in the literature. [0011]
  • Within this field, the processes comprising cross-coupling reactions starting from heterocyclic compounds and phenylalanine derivatives are particularly attractive. [0012]
  • For example, 4-(2-furanyl)-phenylalanine is prepared following a cross-coupling process comprising the reaction between N-(tert-butoxycarbonyl)-tyrosine triflate methyl ester and 2-furanboronic acid in the presence of palladium(0)tetrakis(triphenylphosphine) as described by W. C. Shieh in J Org Chem. 1992, 57, 379-381. [0013]
  • Nevertheless, as reported by the same Author, for the preparation of such a compound with valuable yield, amounts of catalyst equal to 30% in moles compared to 2-furanboronic acid, significantly higher than the ones requested for the conversion of other arylboronics substrates, i.e. phenylboronics, are needed. [0014]
  • An alternative route to the above process for the preparation of thienyl-phenylalanine, essentially comprising a cross-coupling reaction between thienylboronic acids and bromo-phenylalanine in the presence of palladium acetate and tri(o-tolyl)phosphine, has been described by M. J. Burk et al. in J. Am. Chem. Soc. 1994, 116, 10847-10848. [0015]
  • The arylboronic derivatives used as synthetic intermediates in the above processes are in turn prepared from the corresponding aryl-magnesium or aryl-lithium derivatives, by reaction with trialkylborates. [0016]
  • Nevertheless, to avoid the formation of di- or tri-arylboron derivatives as by-products, the preparation of the arylboronic acids, for example 2- and 3-furanboronic acids, requires reaction temperatures particularly low equal to −70° C. (J. Org. Chem. 1984, 49, 5237-5243). [0017]
  • According to an alternative synthetic process, the heteroaryl-phenylalanines can be prepared by cross-coupling between halogenated heterocyclic derivatives and stannyl-phenylalanine derivatives (Bioconjugate Chem., 1993, 4, 574-580); nevertheless the alkyistannanes used for the preparation of stannyl-phenylalanines are highly toxic compounds. [0018]
  • Therefore, the high toxicity and the prolonged and difficult preparation of some intermediates make the cross-coupling processes for the synthesis of heteroaryl-phenylalanine, described in the literature, unsuitable for industrial application [0019]
  • Now we have found a process for the preparation of heteroaryl-phenylalanines by cross-coupling reaction that uses organo-zinc compounds, easily practicable and particularly indicated for an industrial application. [0020]
  • Therefore, object of the present invention is a process for the preparation of heteroaryl-phenylalanines of formula [0021]
    Figure US20020028946A1-20020307-C00003
  • in which [0022]
  • R is a hydrogen atom, a straight or branched C[0023] 1-C4 alkyl groups or a benzyl group;
  • R[0024] 1 is an optionally substituted 5 or 6 membered aromatic heterocyclic group with one or two heteroatoms selected among nitrogen, oxygen and sulphur;
  • that comprises the reaction between a compound of formula [0025]
  • R1—Zn—Y  (III)
  • in which [0026]
  • R[0027] 1 has the above reported meanings and Y is a chlorine, bromine or iodine atom; and a compound of formula
    Figure US20020028946A1-20020307-C00004
  • in which [0028]
  • R has the above reported meanings; [0029]
  • R′ is an optionally protected amino group, [0030]
  • X is an iodine or bromine atom or a methansulfonyloxy, fluoromethansulfonyloxy, p toluensulfonyloxy or trifluoromethansulfonyloxy group; [0031]
  • in the presence of a transition-metal (0) based catalyst; [0032]
  • and, when R′ is a protected amino group, the deprotection reaction of the amino group. [0033]
  • The process object of the present invention is easily practicable and it enables to obtain the heteroaryl-phenylalanines of formula II with high yields, equal to or greater than 80% with respect to the starting compound of formula IV. [0034]
  • The cross-coupling reaction, according to the process object of the present invention, is carried out by reaction between an organo-zinc compound of formula III and a compound of formula IV. [0035]
  • Preferably, compound III and compound IV are used in a molar ratio III:IV from 1:1 to 3:1. [0036]
  • Still more preferably, the molar ratio of the compounds III:IV is from 1:1 to 2:1. [0037]
  • In the process object of the present invention the compounds of formula IV in which X is a iodine atom are preferably used. [0038]
  • The cross-coupling reaction is carried out in the presence of a transition-metal(0) based catalyst. [0039]
  • The amount of the catalyst is preferably from 0.05% to 5% in moles with respect to the organo-zinc compound of formula III. [0040]
  • Preferred examples of transition-metal(0) based catalysts are optionally supported palladium or nickel, in the presence of ligands such as, for example, triphenylphosphine. [0041]
  • The transition-metal(0) based catalysts can be optionally prepared in situ starting from the corresponding salts such as, for example, nickel chloride, cobalt chloride, nickel acetylacetonate, ferric chloride, palladium chloride, lithium tetrachlorocuprate, palladium acetate and palladium acetylacetonate. [0042]
  • Exclusively for practical reasons, palladium tetrakis(triphenylphosphine), nickel tetrakis(triphenylphosphine) or palladium on charcoal in the presence of triphenylphosphine, optionally prepared in situ as described, for example, in Org Synth., 66, 67-74, 1988, are preferred. [0043]
  • The cross-coupling reaction is carried out in the presence of an organic solvent. [0044]
  • Suitable organic solvents are, for example, C[0045] 6-C12 aliphatic hydrocarbons, tetrahydrofuran, di-ethyl ether, methyl-lert-butyl ether, ethylene glycol di-methyl ether, dioxane, toluene, xylene or mixtures thereof.
  • Preferably tetrahydrofuran, toluene or mixtures thereof are used. [0046]
  • Usually the reaction temperature is between 20° C. and the reflux temperature of the reaction mixture. [0047]
  • Preferably, a temperature between 40° C. and 60° C. is used. [0048]
  • From a practical point of view, the use of a compound of formula IV in which R′ is a protected amino group is preferred for the preparation of the compounds of formula II. [0049]
  • Examples of suitable protecting groups are acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, formyl, benzyl, ethoxycarbonyl and phthaloyl. [0050]
  • Preferably, the protective group is tert-butoxycarbonyl or formyl. [0051]
  • The starting compounds of formula IV in which R′ is a protected amino group are known compounds or they are easily prepared according to known methods from the corresponding derivatives of formula IV in which R′ is an amino group (H[0052] 2N—) (Bioconjugate Chem. 1993, 4, 574-580).
  • When R′ is a protected amino group, the compounds of formula II according to the present process are prepared by cross-coupling reaction and subsequent deprotection of the amino group. [0053]
  • The deprotection is carried out according to standard procedures. [0054]
  • For a general reference on the use of protective groups in organic chemistry see Theodora W. Greene and Peter G. M. Wuts “Protective Groups in Organic Synthesis”, John Wiley & Sons, Inc., II Ed., 1991. [0055]
  • Usually, the cross-coupling reaction is carried out starting from a compound of formula IV in which R is different from hydrogen, hence obtaining the corresponding compounds of formula II (R different from hydrogen). From these, by working according to conventional procedures, the corresponding compounds of formula II in which R═H can be obtained. [0056]
  • The starting compounds of formula III are known compounds or they are easily prepared according to known methods. [0057]
  • For example, the compounds of formula III can be prepared by reaction of the corresponding heteroaryl-lithium or heteroaryl-magnesium derivatives with an anhydrous zinc halide, e.g. zinc chloride, as likewise reported in Heterocycles, Vol. 31, No 12, 1990, 2181-2186. Examples of compounds of formula II, that can be prepared according to the process object of the present invention, are the compounds in which the R[0058] 1 group is an aromatic heterocyclic group such as, for example, thiazole, isoxazole, oxazole, isothiazole, pyrazole, imidazole, thiophene, pyrrole, pyridine, pyrimidine, pyrazine, pyridazine and furan.
  • Specific examples of compounds of formula II are: [0059]
  • 4-(2-thiazolyl)-phenylalanine; [0060]
  • 4-(2-pyridyl)-phenylalanine; [0061]
  • 4-(3-pyridyl)-phenylalanine; [0062]
  • 4-(2-furyl)-phenylalanine; [0063]
  • 4-(3-furyl)-phenylalanine; [0064]
  • 4-(5-pyrimidinyl)-phenylalanine; [0065]
  • 4-(2-pyrazinyl)-phenylalanine; [0066]
  • 4-(2-thienyl)-phenylalanine; [0067]
  • 4-(3 -thienyl)-phenylalanine; [0068]
  • and the corresponding methyl and ethyl esters. [0069]
  • According to a particularly advantageous aspect of the process object of the present invention, the starting compounds of formula III are prepared in situ from the corresponding heteroaryl-lithium or heteroaryl-magnesium derivatives and hence directly used in the cross-coupling reaction. [0070]
  • More particularly, the heteroaryl-lithium or heteroaryl-magnesium derivatives are reacted with an anhydrous zinc halide, in the presence of the same solvent used for the cross-coupling reaction, to obtain the corresponding heteroaryl-zinc derivatives of formula III. [0071]
  • Therefore, the in situ so prepared compounds of formula III are reacted with the compounds of formula IV, according to the process object of the present invention. [0072]
  • The preparation of compounds of formula III is carried out using a molar ratio anhydrous zinc halide: heteroaryl-lithium or heteroaryl-magnesium derivative from 1:1 to 3:1. [0073]
  • Preferably, the heteroaryl-zinc derivatives of formula III are prepared with anhydrous zinc chloride. [0074]
  • The heteroaryl-lithium or heteroaryl-magnesium derivatives are known compounds or they are easily prepared according to known methods, as described, for example. in J. Am. Chem. Soc. 1952, 74, 6260-6262 or in the just mentioned Heterocycles, Vol. 31, No. 12, 1990, 2181-2186. [0075]
  • In a preferred embodiment of the process object of the present invention, the compounds of formula II are prepared starting from the corresponding heteroaryl-magnesium derivatives, by their reaction with an anhydrous zinc halide and subsequent cross-coupling reaction of the resultant compounds of formula III, in the same medium, as previously described. [0076]
  • The compounds of formula II can be used as synthetic intermediates for the preparation of compounds endowed with pharmacological activity such as, for example, the N-mercaptoacyl derivatives of phenylalanine of formula I, as disclosed in the just mentioned International patent application no. WO 97/24342. [0077]
  • In a particularly preferred embodiment, the process object of the present invention is used for the preparation of the compounds endowed with pharmacological action described in the aforesaid International patent application. [0078]
  • In a preferred embodiment of the process object of the present invention, a suitable amount of heteroaryl-magnesium halide is treated with an anhydrous zinc halide in a molar ratio respectively equal to 1:2, at room temperature and in the presence of a suitable solvent. [0079]
  • Therefore the compound of formula IV, properly protected, is added to the reaction mixture containing the in situ so prepared compound of formula III. [0080]
  • The cross-coupling reaction is carried out in the presence of catalytic amounts, for example equal to 1% in moles, of an in situ prepared palladium based catalyst. [0081]
  • The compounds of formula II, in the protected form, are thus obtained, in high yields, by heating the reaction mixture. [0082]
  • The subsequent deprotection reaction, carried out according to standard procedures, leads to the compounds of formula II. [0083]
  • The resultant compounds of formula II can be used as such, for example as synthetic intermediates for the preparation of pharmacologically active compounds. [0084]
  • The process object of the present invention is easily practicable and it enables to obtain the heteroaryl-phenylalanines of formula II with high yields and with mild reaction conditions. [0085]
  • Moreover, starting from a compound of formula IV as a single stereoisomer, the process object of thre present invention enables to obtain the compounds of formula II with a high optical purity, without any racemization. [0086]
  • Finally, the use of particularly stable intermediates, easily obtainable and usable in situ for the subsequent reactions without any further purification step, makes the process object of the present invention particularly suitable for the industrial application. With the aim to illustrate the present invention the following examples are now given.[0087]
  • EXAMPLE 1
  • Preparation of N-(tert-butoxycarbonyl)4-(2-thiazolyl)-L-phenylalanine methyl ester [0088]
  • A solution of 2-thiazolyl magnesium bromide, prepared starting from 2-bromo-thiazole (0.528 Kg; 3.22 moles) and magnesium turnings (0.093 Kg; 3.82 moles) in a 1:1 mixture of tetrahydrofuran:toluene (1.8 l), was slowly added in 2 hours to a suspension, prepared by slow adding anhydrous zinc chloride (0.853 Kg; 6,27 moles) in tetrahydrofuran (1.92 l ), under stirring and in an inert atmosphere at the temperature of 30° C. [0089]
  • The mixture was heated at 50° C. and N-(tert-butoxycarbonyl)-4-iodo-L-phenylalanine methyl ester (1.0 Kg; 2.34 moles) was gradually added. [0090]
  • A previously prepared mixture of palladium acetate (8 g, 0.036 moles) and triphenylphosphine (19.2 g; 0.072 moles) was added to the resultant mixture. [0091]
  • The mixture, kept under stirring at the temperature of 50° C. for 2 hours up to completion of the reaction (TLC hexane: ethyl acetate=7:3), was then cooled at room temperature and poured into an ice and water (3 Kg) bath containing toluene (1 l) [0092]
  • At that time glacial acetic acid (130 g) was added and the phases were separated. The aqueous phase was extracted with toluene (0.5 l) and the combined organic phases were washed twice with water (2.2 l) and evaporated to dryness under vacuum affording N-(tert-butoxycarbonyl)-4-(2-thiazolyl)-L-phenylalanine methyl ester (1.19 Kg), used as such in the subsequent reaction. [0093]
  • EXAMPLE 2
  • Preparation of N-(tert-butoxycarbonyl)-4-(2-thiazolyl)-D,L-phenylalanine methyl ester [0094]
  • A solution of 2-thiazolyl magnesium bromide prepared by 2-bromo-thiazole (1.8 g; 11 mmoles) and magnesium turnings (320 mg; 13.1 mmoles) in a 1:1 mixture of tetrahydrofuran:toluene (6.6 ml) was gradually added in 0.5 hours to a suspension, prepared by gradually adding anhydrous zinc chloride (3 g; 22 mmoles) to tetrahydrofuran (6.6 ml), kept under stirring and under inert atmosphere at 30° C. [0095]
  • Then, the mixture was heated to 50° C. and N-tert-butoxycarbonyl)-4-bromo-D,L-phenylalanine methyl ester (1.6 g; 4.5 mmoles) was added. [0096]
  • Palladium acetate (33.6 mg; 0.15 mmoles) and triphenylphosphine (118 mg, 0.45 mmoles) were added to the resultant mixture. [0097]
  • The mixture, kept under stirring at 50° C. for 15 hours, was then cooled up to room temperature and poured into an ice and water bath (10 ml) containing toluene (10 ml). [0098]
  • Then, glacial acetic acid (about 1 g) was added and the phases were separated The organic phase was evaporated to dryness. [0099]
  • The residue consisted of about 70% of N-(tert-butoxycarbonyl)-4-(2-thiazolyl)-D,L-phenylalanine methyl ester and of about 15% of starting compound (TLC eluent hexane:ethylacetate=6:4). [0100]
  • EXAMPLE 3
  • Preparation of N-formyl-4-(2-thiazolyl)-L-phenylalanine methyl ester [0101]
  • By working in a way similar to that described in example 1 but starting from N-formyl-4-iodo-L-phenylalanine methyl ester, N-formyl-4-(2-thiazolyl)-L-phenylalanine methyl ester was obtained (yield>90%) as a crude to be used as such without any further purification. [0102]
  • EXAMPLE 4
  • Preparation of 4-(2-thiazolyl)-L-phenylalanine methyl ester dihydrochloride [0103]
  • Thionyl chloride (0.48 Kg; 4.03 moles) was added dropwise, in 1.5 hours, to a solution of N-(tert-butoxycarbonyl)-4-(2-thiazolyl)-L-phenylalanine methyl ester (1.208 Kg; 2.06 moles), prepared as described in example 1, in methanol (1.6 l), kept under stirring, under inert atmosphere and at a temperature of 15° C. [0104]
  • At the end of the addition, the suspension was allowed to warm to 25° C. and kept under stirring for 1 hour. [0105]
  • Methylethylketone (3.4 l) was then added to the resultant mixture and, by heating to reflux, the mixture of solvents (1.9 l) was distilled. [0106]
  • The resultant suspension was cooled to 20° C. and the formed precipitate was filtered and washed with methylethylketone (3×0.3 l) yielding, after drying under vacuum, 4-(2-thiazolyl)-L-phenylalanine methyl ester dihydrochloride [820 g; 91.5% yield calculated on N-(tert-butoxycarbonyl)-4-iodo-L-phenylalanine methyl ester described in example 1; HPLC titre 87%]. [0107]

Claims (11)

1. A process for the preparation of heteroaryl-phenylalanines of formula
Figure US20020028946A1-20020307-C00005
in which
R is a hydrogen atom, a C1-C4 straight or branched alkyl group or a benzyl group;
R1 is an optionally substituted 5 or 6 membered aromatic heterocyclic group with one or two heteroatoms selected among nitrogen, oxygen or sulphur;
that comprises the reaction between a compound of formula
R1—Zn—Y  (iii)
in which
R1 has the above reported meanings and Y is a chlorine, bromine or iodine atom, and a compound of formula
Figure US20020028946A1-20020307-C00006
in which
R has the above reported meanings;
R′ is an optionally protected amino group,
X is an iodine or bromine atom or a methansulfonyloxy, fluoromethansulfonyloxy, p,toluensulfonyloxy, or trifluoromethansulfonyloxy group;
in the presence of a transition-metal (0) based catalyst;
and, when R′ is a protected amino group, the deprotection reaction of the amino group.
2. A process according to claim 1 in which the compounds III and IV are used in a molar ratio from 1:1 to 3:1.
3. A process according to claim 2 in which the molar ratio is from 1:1 to 2:1.
4. A process according to claim 1 in which the compound of formula IV wherein X is an iodine atom is used.
5. A process according to claim 1 in which the amount of catalyst is from 0 05% to 5% in moles with respect to the organo-zinc compound of formula III.
6. A process according to claim 1 wherein the catalyst is an optionally supported palladium or nickel-based catalyst, in the presence of ligands.
7. A process according to claim 6 in which the catalyst is selected among palladium tetrakis(triphenylphosphine), nickel tetrakis(triphenylphosphine) or palladium on charcoal in the presence of triphenylphosphine.
8. A process according to claim 1 wherein a compound of formula IV in which R′ is a tert-butoxycarbonylamino group or a formyl amino group is used.
9. A process according to claim 1 in which the compounds of formula III are prepared in situ from the corresponding heteroaryl-lithium or heteroaryl-magnesium derivatives by reaction with an anhydrous zinc halide.
10. A process according to claim 1 for the preparation of a compound of formula II in which R1 is a heterocyclic group selected between thiazolyl and thienyl.
11. A process for the preparation of N-mercaptoacyl derivatives of phenylalanine of formula
Figure US20020028946A1-20020307-C00007
in which R and R1 have the meanings reported in claim 1;
R2 is a C2-C4 straight or branched alkyl group or an aryl or arylalkyl group having from 1 to 6 carbon atoms in the alkyl moiety in which the aryl group is a phenyl or a 5 or 6 membered aromatic heterocyclic group with 1 or 2 heteroatoms selected among nitrogen, oxygen and sulphur, optionally substituted with one or more substituents, the same or different, selected among halogen atoms, hydroxy groups, alkoxy, alkyl, alkylthio, alkylsulfonyl or alkoxycarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety, C1-C3 alkyl groups having one or more fluorine atoms, carboxy groups, nitro groups, amino or aminocarbonyl groups, acylamino groups, aminosulfonyl groups, mono- or di-alkylamino or mono- or di-alkylaminocarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety;
R3 is a mercapto group or a R4COS group convertible in the body into a mercapto group in which R4 is a C1-C4 straight or branched alkyl group or a phenyl group,
that comprises the reaction of a compound of formula
R1—Zn—Y  (III)
with a compound of formula
Figure US20020028946A1-20020307-C00008
in which R, R′, X and Y have the meanings reported in claim 1;
in the presence of a transition-metal(0) based catalyst;
and, when R′ is a protected amino group, the deprotection reaction of the amino group to yield the compound of formula
Figure US20020028946A1-20020307-C00009
in which R and R1 have the above reported meanings.
US09/331,164 1996-12-24 1997-12-15 Process for the preparation of heteroaryl-phenylalanines Expired - Lifetime US6448408B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT96MI002738A IT1289522B1 (en) 1996-12-24 1996-12-24 PROCESS FOR THE PREPARATION OF ETEROARIL-FENILALANINE
ITMI96A2738 1996-12-24
ITMI96A002738 1996-12-24
PCT/EP1997/007024 WO1998028284A1 (en) 1996-12-24 1997-12-15 Process for the preparation of heteroaryl-phenylalanines

Publications (2)

Publication Number Publication Date
US20020028946A1 true US20020028946A1 (en) 2002-03-07
US6448408B1 US6448408B1 (en) 2002-09-10

Family

ID=11375489

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/331,164 Expired - Lifetime US6448408B1 (en) 1996-12-24 1997-12-15 Process for the preparation of heteroaryl-phenylalanines

Country Status (15)

Country Link
US (1) US6448408B1 (en)
EP (1) EP0948492B1 (en)
JP (1) JP4226659B2 (en)
AT (1) ATE203017T1 (en)
BR (1) BR9713924B1 (en)
CA (1) CA2275764C (en)
CZ (1) CZ296240B6 (en)
DE (1) DE69705640T2 (en)
DK (1) DK0948492T3 (en)
ES (1) ES2159892T3 (en)
GR (1) GR3036855T3 (en)
IL (1) IL130364A (en)
IT (1) IT1289522B1 (en)
PT (1) PT948492E (en)
WO (1) WO1998028284A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4452899B2 (en) * 2001-12-13 2010-04-21 味の素株式会社 New phenylalanine derivatives
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277737B1 (en) 1995-12-28 1997-11-12 Zambon Spa TIOLIC DERIVATIVES FOR METALLOPEPTIDASE INHIBITIVE ACTIVITY

Also Published As

Publication number Publication date
ATE203017T1 (en) 2001-07-15
EP0948492A1 (en) 1999-10-13
WO1998028284A1 (en) 1998-07-02
US6448408B1 (en) 2002-09-10
PT948492E (en) 2001-11-30
DK0948492T3 (en) 2001-10-15
GR3036855T3 (en) 2002-01-31
JP2001506662A (en) 2001-05-22
ITMI962738A1 (en) 1998-06-24
BR9713924B1 (en) 2009-01-13
CA2275764C (en) 2007-09-18
ES2159892T3 (en) 2001-10-16
CA2275764A1 (en) 1998-07-02
IL130364A0 (en) 2000-06-01
BR9713924A (en) 2000-03-21
DE69705640T2 (en) 2002-05-02
DE69705640D1 (en) 2001-08-16
CZ296240B6 (en) 2006-02-15
EP0948492B1 (en) 2001-07-11
CZ230799A3 (en) 1999-12-15
IL130364A (en) 2003-07-06
JP4226659B2 (en) 2009-02-18
IT1289522B1 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
Schmidt et al. Amino Acids and Peptides; 58 Synthesis of Optically Active 2-(1-Hydroxyalkyl)-thiazole-4-carboxylic Acids and 2-(1-Aminoalkyl)-thiazole-4-carboxylic Acids
Deboves et al. Direct synthesis of Fmoc-protected amino acids using organozinc chemistry: application to polymethoxylated phenylalanines and 4-oxoamino acids
US6448408B1 (en) Process for the preparation of heteroaryl-phenylalanines
US6211380B1 (en) Process for the preparation of heteroaryl-zinc halides
MXPA99005931A (en) Process for the preparation of heteroaryl-phenylalanines
Zavozin et al. Synthesis of thiazole derivatives bearing an incorporated Z-5-aminopent-3-enoic acid fragment
US6455726B2 (en) Manufacturing method
EP1533306A1 (en) Azlactone compound and method for preparation thereof
CA2380169C (en) A process for preparing 4-cyano-2-aminomethylthiazole
US6506903B1 (en) Process for producing 4-thiazolylmethyl derivative
Smithwick Jr et al. New synthesis of N. alpha., NG, G-tribenzyloxycarbonyl-L-arginine and related derivatives
US20040082759A1 (en) Process for preparing distamycin derivatives
JP3233806B2 (en) Method for producing sulfenylacetic acid derivative
JP2005517703A (en) Process for the preparation of 4-hetero-substituted phenylalanine derivatives
CN112010722A (en) Synthesis method of E-type beta-thiocyanatelamide derivative
JP2007502311A (en) Synthesis of heterocyclic compounds
MXPA99006648A (en) Process for the preparation of heteroaryl-zinc halides
KR100494058B1 (en) Novel 1-acyl(or aroyl)pyridazin-6-one derivatives, process for preparation of the same and its use as acylating agent
JPH0742286B2 (en) Thiazolidine derivative
JP2003512462A (en) Stereoselective synthesis of oxazoline derivatives
JPH09136885A (en) Thiirane derivative and its production
KR20040100520A (en) Process for preparing 2-thiophenecarboxaldehyde derivatives
EP1411048A1 (en) Preparation of 2-bromo-pyrimidines and 2-iodo-pyrimidines

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZAMBON GROUP S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VILLA, MARCO;PAIOCCHI, MAURIZIO;ARRIGHI, KATIUSCIA;REEL/FRAME:010131/0736

Effective date: 19990614

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12